As FCA Meets 340B, Geyser Of Qui Tam Suits May Erupt
A Ninth Circuit ruling that allows two of the most contentious laws in healthcare to work in concert in a fraud case amplifies the legal risk drugmakers face in a program...To view the full article, register now.
Already a subscriber? Click here to view full article